Summary & Overview
Benign Prostatic Hypertrophy without MCC: Inpatient Reimbursement Overview
DRG 726 addresses inpatient stays for benign prostatic hypertrophy without Major Complication or Comorbidity, encompassing admissions for surgical and non-surgical management of prostatic enlargement. Correct assignment matters for Medicare inpatient reimbursement because it determines relative payment rates among related Diagnosis-Related Groups based on clinical complexity and resource use.
DRG 726 Overview
DRG 726 covers inpatient admissions for benign prostatic hypertrophy without Major Complication or Comorbidity and typically includes patients admitted for procedures such as transurethral resection of the prostate or observation for urinary obstruction related to benign prostatic enlargement. This Diagnosis-Related Group groups clinically similar cases with comparable resource use to determine Medicare inpatient payment. It is important for reimbursement because the Presence or absence of Major Complication or Comorbidity affects payment relative to other related Diagnosis-Related Groups. Accurate clinical coding and documentation drive correct assignment to this Diagnosis-Related Group and corresponding Medicare payment.